GERN Stock Analysis: Buy, Sell, or Hold?
GERN - Geron Corp
$1.66
0.00 (0.00%)
▲
5d:
+7.79%
30d:
+12.93%
90d:
+25.76%
BUY
HIGH Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 06, 2026
Smart Money Accumulation
GERN is down 4.1% this week, but smart money is accumulating calls. Top strike: $2 2026-06-18 with 3,608 OI. Call ratio: 100% View Scanner →
Strength: 7.1/10
Get Alerted When GERN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GERN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: GERN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: GERN is currently trading at $1.66, which is considered slightly high relative to its 30-day fair value range of $1.47 to $1.70. The stock's valuation (Forward PE: 20.8) is in line with its historical norms (19.5). At these levels, the market is pricing in 2.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GERN is in a strong uptrend. The price is approaching resistance at $1.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GERN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $3.40 (+104.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GERN is in a strong uptrend. The price is approaching resistance at $1.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GERN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $3.40 (+104.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$1.47 -
$1.70
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 104.8% below Wall St target ($3.40)
- NEUTRAL: Market pricing in 2.2% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$1.47 -
$1.70
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.38
Resistance Level
$1.68
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.75
Wall Street Target
$3.40
(+104.8%)
Revenue Growth (YoY)
1.0%
Profit Margin
-45.4%
Valuation Premium vs History
+2.2% premium
PE vs Historical
20.8 vs 19.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.2%
(market-implied from PE analysis)
1-Year Target
$1.70
(+2%)
2-Year Target
$1.73
(+4%)
3-Year Target
$1.77
(+7%)
3-Yr Target (if PE normalizes)
(PE: 21→20)
PE COMPRESSION
$1.67
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: April 02, 2026 6:54 PM ET
Data refreshes hourly during market hours. Next update: 7:54 PM
Data refreshes hourly during market hours. Next update: 7:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GERN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 61 BUY |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$290 | 53 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 53 HOLD |
Advanced GERN Option Strategies
Professional options setups generated by AI based on today's GERN price and gamma walls.
